FDA Approved & Pharmacopeial Drug Library | FDA 上市及药典收录化合物库 | MedChemExpress (MCE)
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
MedChemExpress (MCE) | 生产商 | 美国 | 现货 |
性能特点
New drug development is a time-consuming and high-cost process. Drug repurposing (also called dr
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,498 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.更多产品详情查看:www.medchemexpress.cn/screening/fda-approved-pharmacopeial-drug-library.html
FDA Approved & Pharmacopeial Drug Library | FDA 上市及药典收录化合物库 | MedChemExpress (MCE)信息由MedChemExpress (MCE)为您提供,如您想了解更多关于FDA Approved & Pharmacopeial Drug Library | FDA 上市及药典收录化合物库 | MedChemExpress (MCE)报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途